A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This study will have a safety lead in phase and a randomization phase.
Epistemonikos ID: 7ab0ca2c167772cbf26416244e8760a905067e98
First added on: May 21, 2024